Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
21
OCX Quote, Financials, Valuation and Earnings
Last price:
$2.23
Seasonality move
:
11.63%
Day range:
$2.15 - $2.27
52-week range:
$1.98 - $3.82
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
33.60x
P/B ratio:
3.83x
Volume:
78.2K
Avg. volume:
117.6K
1-year change:
-21.35%
Market cap:
$37.2M
Revenue:
$1.5M
EPS (TTM):
-$4.54
Analysts' Opinion
-
Consensus RatingOncoCyte has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, OncoCyte has an estimated upside of 86.65% from its current price of $2.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.21.
Fair Value
-
According to the consensus of 0 analysts, OncoCyte has 86.65% upside to fair value with a price target of -- per share.
OCX vs. S&P 500
-
Over the past 5 trading days, OncoCyte has underperformed the S&P 500 by -2.81% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
OncoCyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OncoCyte revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter OncoCyte reported revenues of $115K.
Earnings Growth
-
OncoCyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter OncoCyte reported earnings per share of -$0.98.
Enterprise value:
33.8M
EV / Invested capital:
3.49x
Price / LTM sales:
33.60x
EV / EBIT:
--
EV / Revenue:
47.73x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$115K
Return On Assets:
-57.93%
Net Income Margin (TTM):
-6085.19%
Return On Equity:
-211.42%
Return On Invested Capital:
-211.42%
Operating Margin:
-5543.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -$1.3M | $1.5M | $709K | $429K | $115K | |
| Gross Profit | $2.6M | $503K | -$115K | $248K | $50K | |
| Operating Income | -$13M | -$23.4M | -$22.9M | -$5.1M | -$6.4M | |
| EBITDA | -$28.6M | -$1.9M | -$41.8M | -$6M | -$13.1M | |
| Diluted EPS | -$13.10 | -$9.51 | -$4.54 | -$0.81 | -$0.98 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $12M | $47.6M | $36.6M | $16.9M | $4.8M | |
| Total Assets | $57.8M | $168.3M | $157.3M | $81.6M | $70.2M | |
| Current Liabilities | $8.9M | $13.4M | $13M | $8M | $9.1M | |
| Total Liabilities | $23.1M | $69M | $80.5M | $44M | $60.5M | |
| Total Equity | $34.6M | $99.3M | $76.9M | $37.6M | $9.7M | |
| Total Debt | $4.1M | $1.7M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$43M | -$28.5M | -$19.8M | -$3.8M | -$5.6M | |
| Cash From Investing | -$3.9M | -$1.8M | -$199K | $214K | -$87K | |
| Cash From Financing | $35.6M | $12.1M | $9.6M | -$30K | -$255K | |
| Free Cash Flow | -$46.9M | -$29.4M | -$20.3M | -$3.8M | -$5.6M | |
OCX
Sector
Market Cap
$37.2M
$44.6M
Price % of 52-Week High
57.85%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-21.35%
-29.09%
Beta (5-Year)
0.934
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.27
200-day SMA
Sell
Level
$2.89
Bollinger Bands (100)
Sell
Level
2.6 - 3.18
Chaikin Money Flow
Sell
Level
-103.8M
20-day SMA
Sell
Level
$2.39
Relative Strength Index (RSI14)
Sell
Level
30.62
ADX Line
Sell
Level
7.14
Williams %R
Neutral
Level
-58.9286
50-day SMA
Sell
Level
$2.73
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
100.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.2078)
Sell
CA Score
(Annual)
Level (-2.596)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (5.4569)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.
Stock Forecast FAQ
In the current month, OCX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCX average analyst price target in the past 3 months is --.
-
Where Will OncoCyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that OncoCyte share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About OncoCyte?
Analysts are divided on their view about OncoCyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OncoCyte is a Sell and believe this share price will drop from its current level to --.
-
What Is OncoCyte's Price Target?
The price target for OncoCyte over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OncoCyte is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCX?
You can purchase shares of OncoCyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OncoCyte shares.
-
What Is The OncoCyte Share Price Today?
OncoCyte was last trading at $2.23 per share. This represents the most recent stock quote for OncoCyte. Yesterday, OncoCyte closed at $2.21 per share.
-
How To Buy OncoCyte Stock Online?
In order to purchase OncoCyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
